Kymera Therapeutics, Inc. (KYMR) - Q1 2026 10-Q Summary
Business Context and Reporting Period
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics using targeted protein degradation (TPD). This report covers the quarterly period ended March 31, 2026. The company has no approved products and generates revenue primarily through strategic collaboration agreements.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $34.4 million | $22.1 million |
| Total Operating Expenses | $118.5 million | $96.5 million |
| Net Loss | $(69.2) million | $(65.6) million |
| Net Loss Per Share (Basic & Diluted) | $(0.71) | $(0.82) |
| Cash, Cash Equivalents & Marketable Securities | $1,546 million | $1,598 million (Dec 31, 2025) |
| Accumulated Deficit | $(1,135) million | $(1,066) million (Dec 31, 2025) |
| Operating Cash Flow | $(88.8) million | $(79.2) million |
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased by $12.3 million (55%) compared to Q1 2025. This was driven entirely by the recognition of $34.4 million in revenue from the Gilead Sciences collaboration agreement, whereas Q1 2025 revenue was derived from the Sanofi agreement.
- Expense Increase: Total operating expenses rose by $22.0 million. Research and Development (R&D) expenses increased by $17.9 million, primarily due to a $12.6 million increase in costs for the STAT6 program and higher personnel/occupancy costs. General and Administrative (G&A) expenses increased by $4.1 million due to legal, professional, and personnel costs.
- Interest Income: Other income increased by $6.1 million to $14.9 million, reflecting higher interest earned on the company's substantial cash and marketable securities balances.
- Liquidity: Cash and cash equivalents decreased from $357.0 million at year-end 2025 to $144.1 million at March 31, 2026, largely due to net cash used in operating activities and net purchases of marketable securities.
Guidance, Outlook, and Management Commentary
- Capital Runway: Management believes existing cash, cash equivalents, and marketable securities of $1.546 billion are sufficient to fund operations into 2029, beyond multiple clinical inflection points.
- Subsequent Event (Gilead): In April 2026, Gilead Sciences exercised its option to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader. This triggered a $45 million milestone payment, expected to be received and recognized as revenue in Q2 2026.
- Pipeline Progress:
- STAT6 (KT-621): Fast Track Designation received for atopic dermatitis (Dec 2025) and moderate to severe asthma (April 2026). Phase 2b trials ongoing.
- IRF5 (KT-579): Phase 1 clinical trial ongoing in healthy volunteers.
- IRAK4 (KT-485): Sanofi plans to advance this candidate into clinical testing in 2026.
- Risks: The company highlights risks related to the unproven nature of its TPD platform, potential delays in clinical trials, dependence on third-party manufacturers, and the need for substantial additional funding if capital markets deteriorate or development timelines extend.
Investor Verification Checklist
- Verify the timing and receipt of the $45 million Gilead milestone payment expected in Q2 2026.
- Monitor the progress and data readouts from the STAT6 (KT-621) Phase 2b trials in atopic dermatitis and asthma.
- Assess the impact of the Sanofi decision to discontinue KT-474 in favor of KT-485 on the IRAK4 program timeline.
- Review the company's burn rate and capital allocation strategy to ensure the runway into 2029 remains valid given increasing R&D costs.
- Track the status of the sublease for the former Watertown facility to mitigate potential impairment charges or lease obligations.